Alto Neuroscience ANRO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -38.9%-0.8pp | -41.8%— | -45%— | -42.8%— | -38%— | |
| Liquidity | ||||||
| Current ratio | 20.5×-2.0× | 15.7×-1.2× | 15.4×+2.3× | 18.4×-1.4× | 22.5×-3.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×0.0× | 0.2×+0.1× | 0.2×+0.1× | 0.2×+0.1× | |
| Per Share | ||||||
| Book value per share | $7.40+43.9% | $5.24-14.9% | $4.12-32.8% | $4.56-31.8% | $5.14-53.1% | |
| Valuation | ||||||
| Market capitalization | $874.19M+1,335% | $552.98M+385% | $108.85M-64.7% | $67.68M-76.4% | $58.48M-85.8% | |
| Price / book | 3.6×+3.2× | 3.7×+2.9× | 1×-0.9× | 0.5×-1.1× | 0.4×-1.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Alto Neuroscience's ratios come from?
- Every ratio is computed from Alto Neuroscience's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.